Trial Profile
Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Gamma tocotrienol (Primary) ; Pentoxifylline (Primary)
- Indications Gastrointestinal disorders; Radiation-induced abnormalities
- Focus Therapeutic Use
- Acronyms PPALM
- 01 Mar 2022 Status has been changed to discontinued, as per Results published in the Radiotherapy and Oncology
- 01 Mar 2022 Results published in the Radiotherapy and Oncology
- 25 Jul 2019 Planned End Date changed from 5 Jan 2019 to 30 Sep 2019.